AXIM Biotechnologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	0.09	0.04	0.01	0.06	-	-
Revenue Growth (YoY)	257.95%	345.27%	-85.32%	-	-	-
Cost of Revenue	0	-	-	-	-	-
Gross Profit	0.09	0.04	0.01	0.06	-	-
Selling, General & Admin	1.88	2.24	4.08	5.67	4.51	3.11
Research & Development	0.09	0.13	0.15	0.28	0.43	-
Operating Expenses	2.4	2.79	4.66	8.07	4.95	3.11
Operating Income	-2.31	-2.75	-4.65	-8.01	-4.95	-3.11
Interest Expense	-0.78	-1.2	-1.88	-0.49	-0.32	-0.3
Interest & Investment Income	-	-	0	0	0	-
Other Non Operating Income (Expenses)	-0.03	-3.31	0.77	0.02	0.12	0.06
EBT Excluding Unusual Items	-3.13	-7.27	-5.76	-8.47	-5.15	-3.35
Gain (Loss) on Sale of Investments	-	-	-	-	-0.21	0.38
Asset Writedown	-	-	-	-5.97	-	-
Legal Settlements	-0.96	-0.96	-	-	-	-
Other Unusual Items	-0.05	0.16	-0.48	-1.59	-0.92	-
Pretax Income	-4.14	-8.06	-6.24	-16.02	-6.29	-2.97
Earnings From Continuing Operations	-4.14	-8.06	-6.24	-16.02	-6.29	-2.97
Earnings From Discontinued Operations	-	-	-	-0.01	-0.12	-3.48
Net Income	-4.14	-8.06	-6.24	-16.03	-6.41	-6.45
Net Income to Common	-4.14	-8.06	-6.24	-16.03	-6.41	-6.45
Shares Outstanding (Basic)	255	228	165	132	110	62
Shares Outstanding (Diluted)	255	228	165	132	110	62
Shares Change (YoY)	27.42%	37.60%	25.79%	19.16%	78.19%	8.14%
EPS (Basic)	-0.02	-0.04	-0.04	-0.12	-0.06	-0.10
EPS (Diluted)	-0.02	-0.04	-0.04	-0.12	-0.06	-0.11
Free Cash Flow	-0.76	-1.03	-2.05	-2.53	-3.31	-5.04
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.02	-0.03	-0.08
Gross Margin	98.12%	100.00%	100.00%	100.00%	-	-
Operating Margin	-2490.34%	-6960.98%	-52425.60%	-13246.02%	-	-
Profit Margin	-4452.06%	-20394.96%	-70343.09%	-26517.21%	-	-
Free Cash Flow Margin	-820.08%	-2607.67%	-23132.80%	-4180.05%	-	-
EBITDA	-1.88	-2.32	-4.23	-5.89	-4.93	-3.11
D&A For EBITDA	0.43	0.43	0.43	2.12	0.02	0
EBIT	-2.31	-2.75	-4.65	-8.01	-4.95	-3.11

Updated Aug 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.